Clinical

Dataset Information

0

Phase I study of 5-FU + Oxaliplatin + Irinotecan + Levofolinate + Panitumumab as the first-line therapy in patients with KRAS or RAS wild-type metastatic colorectal cancer


ABSTRACT: Interventions: FOLFOXIRI+Panitumumab (Until 12 courses) Panitumumab 6mg/kg/bi-weekly Irinotecan 165-125mg/m2/bi-weekly Oxaliplatin 85mg/m2/bi-weekly Levofolinate 200mg/m2/bi-weekly 5-FU 3200mg/m2/bi-weekly Primary outcome(s): Recommended Dose Study Design: Single arm Non-randomized

DISEASE(S): Kras Or Ras Wild-type Metastatic Colorectal Cancer

PROVIDER: 2630804 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2633522 | ecrin-mdr-crc
| 2633714 | ecrin-mdr-crc
| 2630485 | ecrin-mdr-crc
| 2613998 | ecrin-mdr-crc
| 2630399 | ecrin-mdr-crc
| 2623948 | ecrin-mdr-crc
| 2626811 | ecrin-mdr-crc
| 2630948 | ecrin-mdr-crc
| 2620191 | ecrin-mdr-crc
| 2622610 | ecrin-mdr-crc